Evidence map›Paper›PMID 39557690›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Dopaminergic PET to SPECT domain adaptation: a cycle GAN translation approach.

Leonor Lopes, Fangyang Jiao, Song Xue, Thomas Pyka, Korbinian Krieger, Jingjie Ge, Qian Xu, Rachid Fahmi, Bruce Spottiswoode, Ahmed Soliman and 9 more

Abstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. On Hallucinations in Artificial Intelligence-Generated Content for Nuclear Medicine Imaging (the DREAM Report).Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Review
  6. Article
  7. Review
  8. Article
  9. AI in SPECT Imaging: Opportunities and Challenges.Seminars in nuclear medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Leonor LopesDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.ORCID 0000-0002-9536-6691
Fangyang JiaoDepartment of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
Song XueDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.
Thomas PykaDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.
Korbinian KriegerDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.
Jingjie GeDepartment of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
Qian XuDepartment of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
Rachid FahmiSiemens Medical Solutions USA, Inc., Molecular Imaging, Knoxville, TN, USA.
Bruce SpottiswoodeSiemens Medical Solutions USA, Inc., Molecular Imaging, Knoxville, TN, USA.
Ahmed SolimanSiemens Medical Solutions USA, Inc., Molecular Imaging, Knoxville, TN, USA.
Ralph BuchertDepartment of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Matthias BrendelDepartment of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
Jimin HongDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.
Yihui GuanDepartment of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
Claudio L A BassettiDepartment of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Axel RomingerDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland.
Chuantao ZuoDepartment of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China.
Kuangyu ShiDepartment of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 18, Bern, 3010, Switzerland. kuangyu.shi@unibe.ch.
Ping WuDepartment of Nuclear Medicine / PET Center, Huashan Hospital, Fudan University, Shanghai, 200235, China. wupingpet@fudan.edu.cn.ORCID 0000-0002-2758-1218

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDopamine transporter imaging is routinely used in Parkinson's disease (PD) and atypical parkinsonian syndromes (APS) diagnosis. While [

methodsA CycleGAN was trained on [

resultsFréchet Inception Distance indicated higher similarity between synthetic and real SPECT than between synthetic SPECT and real PET. A deep learning classification model trained on synthetic SPECT achieved sensitivity of 97.2% and specificity of 90.0% on real SPECT images. Striatal specific binding ratios of synthetic SPECT were not significantly different from real SPECT. The striatal left-right differences and putamen binding ratio were significantly different only in the PD cohort. Real PET and real SPECT had higher contrast-to-noise ratio compared to synthetic SPECT. Visual grading analysis scores showed no significant differences between real and synthetic SPECT, although reduced diagnostic performance on synthetic images was observed.

conclusionCycleGAN generated synthetic SPECT images visually indistinguishable from real ones and retained disease-specific information, demonstrating the feasibility of translating [

Indexed as

Image Processing, Computer-AssistedParkinson DiseasePositron-Emission TomographyTomography, Emission-Computed, Single-PhotonAgedDeep LearningDopamine Plasma Membrane Transport ProteinsFemaleHumansMaleMiddle AgedParkinsonian DisordersTropanes2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropaneDopamine Plasma Membrane Transport ProteinsTropanesCFT PETCycle GANDomain adaptationFP-CIT SPECTParkinson’s disease

Identifiers

PMID39557690
PMCPMC11754385

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.